Phase 3 Trial for Novel NSCLC Therapy Announced

Share this content:

(ChemotherapyAdvisor) – Pharmaceutical company OncoGenex (Bothell, WA) announced in a July 10 press release its clinical development plans for custirsen in the treatment of non-small cell lung cancer (NSCLC). The phase 3 clinical trial, which will be initiated in late-2012, will evaluate the potential survival benefit of custirsen in combination with docetaxel as second-line treatment in patients with NSCLC who have progressed after initial, or first-line, platinum-based chemotherapy has failed.

The company plans to enroll approximately 1,100 patients with advanced or metastatic NSCLC in this phase 3, international, randomized, open label study. Investigators will randomize patients to receive custirsen plus docetaxel or docetaxel alone. End points include overall survival and biomarker relationships.

Custirsen acts by a novel mechanism of action – blocking production of clusterin, a cell survival protein that is commonly overexpressed in several cancer types and in response to anticancer treatments. In previously published phase 2 studies that evaluated custirsen in combination with a gemcitabine/platinum-based regimen in first-line NSCLC, patients experienced a median overall survival of 14.1 months, and decreased serum clusterin levels in 95% of patients evaluated, with lower serum clusterin levels correlating with survival outcomes.

Press release

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs